Martin Shkreli
Contributor since: 2011
Company: MSMB Capital
Latest Articles
Martin Shkreli: This Week In Investing (19)
Debt Burden Makes Horizon Pharma An Attractive Short
Nektar Phase III Trials At Risk
BioTime Is Running Out Of Time - Short-Sell Idea
Cytori Is A Compelling Short Sale Opportunity
MannKind Is Simply Running Out Of Cash
Ampio Is A Compelling Short Sale Idea
Avanir - Closing Short Position
Closing Zalicus Short Position: A Lesson In Getting The Timing Right
Human Genome Sciences: Slow Benlysta Launch Results In Good Short Candidate
The Short Case for Mesoblast: Little Upside Left, No Need for a Catalyst
Neoprobe: Why I'm Closing My Short Position
Chelsea Therapeutics: Likely to Double on Safe, Proven Asset
Oncothyreon: Phase III Unlikely to Show Survival Benefit
The Short Case for Zalicus: Not Worth Its Market Cap
Neoprobe: Did the Pivotal Studies Meet Their Primary Endpoints?
Neoprobe: Follow-Up on ASCO, Citizen Petition and Readers' Comments
BioMarin - Fair Value Of $50+: A Step-By-Step Analysis
Star Scientific: Widely Shorted for Good Reason
The Short Case for Neoprobe: Skeptical of Its Primary Asset's Success
Avanir Pharmaceuticals: Compelling Short Sale Opportunity